Line Tang Møllehave1, Allan Linneberg1,2,3, Tea Skaaby1, Nils Knudsen4, Lars Ehlers5, Torben Jørgensen1,6,7, Betina Heinsbæk Thuesen1. 1. Research Centre for Prevention and Health, The Capital Region of Denmark, Copenhagen, Denmark. 2. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3. Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark. 4. Department of Endocrinology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark. 5. Danish Center for Healthcare Improvements, Department of Business and Management, Aalborg University, Aalborg, Denmark. 6. Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 7. Faculty of Medicine, Aalborg University, Aalborg, Denmark.
Abstract
BACKGROUND: Iodine fortification (IF) may contribute to changes in costs of thyroid disease treatment through changes in disease patterns. From a health economic perspective, assessment of the development in costs of thyroid disease treatment in the population is pertinent. OBJECTIVES: To assess the trends in annual medicine and hospital costs of thyroid disease treatment during 1995-2015 in Denmark, i.e., before and after the introduction of mandatory IF in 2000. METHODS: Information on treatments for thyroid disease (antithyroid medication, thyroid hormone therapy, thyroid surgery, and radioiodine treatment) was obtained from nationwide registers. Costs were valued at 2015 prices using sales prices for medicines and the Danish Diagnosis-Related Group (DRG) and Danish Ambulatory Grouping System (DAGS) tariffs of surgeries/radioiodine treatments. Results were adjusted for changes in population size and age and sex distribution. RESULTS: The total direct medicine and hospital costs of thyroid disease treatment increased from EUR ∼190,000 per 100,000 persons in 1995 to EUR ∼270,000 per 100,000 persons in 2015. This was mainly due to linearly increased costs of thyroid hormone therapy and increased costs of thyroid surgery since 2008. Costs of antithyroid medication increased slightly and transiently after IF, while costs of radioiodine treatment remained constant. Costs of thyroid hormone therapy and thyroid surgery did not follow the development in the prevalence of hypothyroidism and structural thyroid diseases observed in concurrent studies. CONCLUSION: The costs of total direct medicine and hospital costs for thyroid disease treatment in Denmark increased from 1995 to 2015. This is possibly due to several factors, e.g., changes in treatment practices, and the direct effect of IF alone remains to be estimated.
BACKGROUND: Iodine fortification (IF) may contribute to changes in costs of thyroid disease treatment through changes in disease patterns. From a health economic perspective, assessment of the development in costs of thyroid disease treatment in the population is pertinent. OBJECTIVES: To assess the trends in annual medicine and hospital costs of thyroid disease treatment during 1995-2015 in Denmark, i.e., before and after the introduction of mandatory IF in 2000. METHODS: Information on treatments for thyroid disease (antithyroid medication, thyroid hormone therapy, thyroid surgery, and radioiodine treatment) was obtained from nationwide registers. Costs were valued at 2015 prices using sales prices for medicines and the Danish Diagnosis-Related Group (DRG) and Danish Ambulatory Grouping System (DAGS) tariffs of surgeries/radioiodine treatments. Results were adjusted for changes in population size and age and sex distribution. RESULTS: The total direct medicine and hospital costs of thyroid disease treatment increased from EUR ∼190,000 per 100,000 persons in 1995 to EUR ∼270,000 per 100,000 persons in 2015. This was mainly due to linearly increased costs of thyroid hormone therapy and increased costs of thyroid surgery since 2008. Costs of antithyroid medication increased slightly and transiently after IF, while costs of radioiodine treatment remained constant. Costs of thyroid hormone therapy and thyroid surgery did not follow the development in the prevalence of hypothyroidism and structural thyroid diseases observed in concurrent studies. CONCLUSION: The costs of total direct medicine and hospital costs for thyroid disease treatment in Denmark increased from 1995 to 2015. This is possibly due to several factors, e.g., changes in treatment practices, and the direct effect of IF alone remains to be estimated.
Entities:
Keywords:
Costs and cost analysis; Epidemiology; Health care costs; Iodine; Thyroid diseases
Authors: Charlotte Cerqueira; Nils Knudsen; Lars Ovesen; Peter Laurberg; Hans Perrild; Lone B Rasmussen; Torben Jørgensen Journal: Eur J Endocrinol Date: 2010-01-18 Impact factor: 6.664
Authors: Lone B Rasmussen; Allan Carlé; Torben Jørgensen; Nils Knudsen; Peter Laurberg; Inge B Pedersen; Hans Perrild; Pernille Vejbjerg; Lars Ovesen Journal: Br J Nutr Date: 2008-01-22 Impact factor: 3.718
Authors: Peter N Taylor; Ahmed Iqbal; Caroline Minassian; Adrian Sayers; Mohd S Draman; Rosemary Greenwood; William Hamilton; Onyebuchi Okosieme; Vijay Panicker; Sara L Thomas; Colin Dayan Journal: JAMA Intern Med Date: 2014-01 Impact factor: 21.873
Authors: Morten Schmidt; Sigrun Alba Johannesdottir Schmidt; Jakob Lynge Sandegaard; Vera Ehrenstein; Lars Pedersen; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2015-11-17 Impact factor: 4.790
Authors: Henry Völzke; Iris Erlund; Alicja Hubalewska-Dydejczyk; Till Ittermann; Robin P Peeters; Margaret Rayman; Monika Buchberger; Uwe Siebert; Betina H Thuesen; Michael B Zimmermann; Stefan Grünert; John H Lazarus Journal: Eur Thyroid J Date: 2018-07-31